Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Rhea-AI Summary
Iovance Biotherapeutics (NASDAQ: IOVA) granted inducement stock options on June 18, 2026 to twenty-seven new non-executive employees. The options cover an aggregate 140,860 shares of common stock under the 2021 Inducement Plan, have a $3.91 exercise price, and vest over three years.
AI-generated analysis. Not financial advice.
Positive
- Inducement options covering 140,860 shares help attract and retain 27 new employees
- Exercise price set at $3.91, aligned with market closing price on grant date
- Three-year vesting with quarterly installments supports long-term employee alignment
Negative
- Inducement stock options introduce potential dilution from up to 140,860 additional shares
News Market Reaction – IOVA
On the day this news was published, IOVA gained 3.84%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Peers on Argus
IOVA was modestly lower ahead of this filing, while close biotech peers showed a mix of small gains and losses. With no peers in the momentum scanner, the move appears more stock-specific than sector-driven.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jun 03 | Regulatory approval | Positive | +15.6% | Australia granted conditional approval for Amtagvi in advanced melanoma patients. |
| Jun 01 | IND clearance | Positive | -3.4% | FDA cleared IND for IL-12 tethered TIL therapy IOV-5001 Phase 1/2 trial. |
| May 22 | Inducement grants | Neutral | -0.2% | Inducement stock options for new employees under 2021 Inducement Plan granted. |
| May 21 | Conference appearance | Neutral | +4.5% | Management scheduled to speak at the 2026 Jefferies Global Healthcare Conference. |
| May 07 | Earnings update | Positive | -13.2% | Strong Q1 revenue growth, guidance, and clinical updates highlighted by management. |
News reactions have been mixed, with some clearly positive regulatory and earnings updates followed by both strong rallies and notable selloffs.
Regulatory & Risk Context
Short positioning is elevated, indicating higher potential for volatility and short-covering dynamics around material news or financings.
An effective ATM shelf allows the company to issue additional common stock over time, which can provide funding flexibility but may dilute existing shareholders if fully utilized.
Market Pulse Summary
This announcement details time-based inducement equity grants totaling 140,860 options at $3.91 per share, complementing an effective ATM of up to $89.65M; with high short interest, future financing usage and execution on Amtagvi commercialization remain key watchpoints.
Key Terms
tumor infiltrating lymphocyte medical
nasdaq listing rule 5635(c)(4) regulatory
exercise price financial
AI-generated analysis. Not financial advice.
SAN CARLOS, Calif., June 19, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer, today announced that on June 18, 2026 (the “Date of Grant”), the Company approved the grant of inducement stock options covering an aggregate of 140,860 shares of Iovance’s common stock to twenty-seven new, non-executive employees.
The awards were granted under Iovance’s Amended and Restated 2021 Inducement Plan, which provides for the granting of equity awards to new employees of Iovance by the Company’s compensation committee in accordance with Nasdaq Listing Rule 5635(c)(4). Each of the stock options granted as referenced in this press release has an exercise price of
About Iovance Biotherapeutics, Inc.
Iovance Biotherapeutics, Inc. aims to be the global leader in innovating, developing, and delivering tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer. We are pioneering a transformational approach to cure cancer by harnessing the human immune system’s ability to recognize and destroy diverse cancer cells in each patient. The Iovance TIL platform has demonstrated promising clinical data across multiple solid tumors. Iovance’s Amtagvi® is the first FDA-approved T cell therapy for a solid tumor indication. We are committed to continuous innovation in cell therapy, including gene-edited cell therapy, that may extend and improve life for patients with cancer. For more information, please visit www.iovance.com.
Amtagvi® and its accompanying design marks, Proleukin®, Iovance®, and IovanceCares™ are trademarks and registered trademarks of Iovance Biotherapeutics, Inc. or its subsidiaries. All other trademarks and registered trademarks are the property of their respective owners.
Forward-Looking Statements
Certain matters discussed in this press release are “forward-looking statements” of Iovance Biotherapeutics, Inc. (hereinafter referred to as the “Company,” “we,” “us,” or “our”) within the meaning of the Private Securities Litigation Reform Act of 1995 (the “PSLRA”). Without limiting the foregoing, we may, in some cases, use terms such as “predicts,” “believes,” “potential,” “achievable,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “forecast,” “guidance,” “outlook,” “may,” “can,” “could,” “might,” “will,” “should,” or other words that convey uncertainty of future events or outcomes and are intended to identify forward-looking statements. Forward-looking statements are based on assumptions and assessments made in light of management’s experience and perception of historical trends, current conditions, expected future developments, and other factors believed to be appropriate. Forward-looking statements in this press release are made as of the date of this press release, and we undertake no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties, and other factors, many of which are outside of our control, that may cause actual results, levels of activity, performance, achievements, and developments to be materially different from those expressed in or implied by these forward-looking statements. Important factors that could cause actual results, developments, and business decisions to differ materially from forward-looking statements are described in the sections titled "Risk Factors" in our filings with the U.S. Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q.
CONTACTS
Investors
IR@iovance.com
650-260-7120 ext. 150
Media
PR@iovance.com
650-260-7120 ext. 150
